Jo Vandorpe

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Mutations in the epidermal growth factor receptor (EGFR) have been reported as predictive markers of tumour response to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Although the “common” EGFR mutations have been associated with response to EGFR-TKIs, the correlation with response to treatment for many other rare(More)
  • 1